Background
Methods
Search strategy and selection criteria
Data extraction and quality assessment
Data synthesis and analysis
Results
Study characteristics
Study Characteristics | OECD (n = 20) | Non-OECD (n = 14) | ||
---|---|---|---|---|
Number of papers | Reference number | Number of papers | Reference number | |
Study Design: | ||||
Retrospective observational | 12 | 10 | ||
Prospective observational | 5 | 1 | [46] | |
Cross-sectional | 3 | 3 | ||
Number of study participants: | ||||
0–50 | 1 | [21] | 1 | [38] |
51–100 | 5 | 2 | ||
101–200 | 7 | 2 | ||
201–500 | 4 | 2 | ||
501–1000 | 3 | 5 | ||
1000+ | 0 | 2 | ||
Method of faecal sampling: | ||||
Stool sample | 14 | 9 | ||
Rectal swab | 5 | 5 | ||
Stool sample or rectal swab | 1 | [29] | 0 | |
Age range of childrena: | ||||
Neonates (0–90 days) | 3 | 0 | ||
0–5 years | 9 | 7 | ||
5–17 years | 4 | 3 | ||
0–17 years | 5 | 4 | ||
Antibiotics reported: | ||||
Ampicillin | 15 | 12 | ||
Co-amoxiclav | 5 | 2 | ||
Co-trimoxazole | 4 | 10 | ||
Trimethoprim | 7 | 2 | ||
Nitrofurantoin | 3 | 2 | ||
Ciprofloxacin | 4 | 12 | ||
Ceftazidime | 4 | 3 | ||
Tetracycline | 13 | 10 | ||
Chloramphenicol | 11 | 10 | ||
Previous exposure to antibioticsb: | ||||
0–2 weeks | 2 | 0 | ||
0–3 weeks | 0 | 1 | [37] | |
0–1 month | 1 | [19] | 0 | |
0–3 months | 1 | [27] | 1 | [49] |
0–6 months | 0 | 0 | ||
0–1 year | 0 | 0 |
Prevalence of resistance in faecal E. coli from asymptomatic children
Antibiotics | OECD | Non-OECD | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Pooled prevalence (95 % CI) | Number of isolates tested | Number of studies | I2 | Ref No. | Pooled prevalence (95 % CI) | Number of isolates tested | Number of studies | I2 | Ref No. | |
Tetracycline | 37.7 % (25.9–49.7 %) | 2438 | 13 (9 countries) | 19.5 % | 80.0 % (59.7–95.3 %) | 5401 | 10 (8 countries) | 62.9 % | ||
Ampicillin | 37.6 % (24.9–54.3 %) | 3053 | 15 (11 countries) | 34.6 % | 67.2 % (45.8–84.9 %) | 6139 | 12 (10 countries) | 58.1 % | ||
Trimethoprim | 28.6 % (2.2–71.0 %) | 862 | 7 (4 countries) | 47.2 % | 81.3 % (40.4–100 %) | 359 | 2 (3 countries) | 50.3 % | ||
Chloramphenicol | 13.4 % (5.2–24.0 %) | 2224 | 11 (8 countries) | 58.1 % | 44.5 % (24.1–66.6 %) | 5665 | 10 (9 countries) | 39.0 % | ||
Co-trimoxazole | 10.8 % (5.7–16.7 %) | 1007 | 4 (4 countries) | 33.5 % | 59.5 % (31.3–85.7 %) | 5439 | 10 (6 countries) | 61.4 % | ||
Co-amoxiclav | 7.2 % (1.8–13.5 %) | 1066 | 5 (5 countries) | 37.9 % | 18.1 % (14.7–21.6 %) | 745 | 2 (2 countries) | 8.8 % | ||
Ciprofloxacin | 5.1 % (0.2–17.8 %) | 586 | 4 (4 countries) | 36.0 % | 9.3 % (3.4–17.2 %) | 6231 | 12 (7 countries) | 60.3 % | ||
Nitrofurantoin | 4.4 % (0.6–9.3 %) | 673 | 3 (3 countries) | 54.4 % | 7.3 % (5.9–9.7 %) | 715 | 2 (2 countries) | 0.0 % | ||
Ceftazidime | 0.3 % (0.1–0.8 %) | 177 | 4 (4 countries) | 0.0 % | 5.0 % (0.7–15.6 %) | 654 | 3 (3 countries) | 28.8 % |